High-throughput crystallography for lead discovery in drug design.
about
Prodepth: predict residue depth by support vector regression approach from protein sequences onlyLost in Translation (LiT): IUPHAR Review 6Membrane protein structure determination - the next generationAutomated harvesting and processing of protein crystals through laser photoablationHigh-density grids for efficient data collection from multiple crystalsOperator-assisted harvesting of protein crystals using a universal micromanipulation robotLeveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiCrystal packing modifies ligand binding affinity: The case of aldose reductaseStructure determination of LpxA from the lipopolysaccharide-synthesis pathway ofAcinetobacter baumanniiIntegrated biophysical approach to fragment screening and validation for fragment-based lead discoveryHigh-Throughput Interrogation of Ligand Binding Mode Using a Fluorescence-Based AssayRecent progress in robot-based systems for crystallography and their contribution to drug discoveryComparing binding modes of analogous fragments using NMR in fragment-based drug design: application to PRDX52.2 Å resolution cryo-EM structure of β-galactosidase in complex with a cell-permeant inhibitorFeatures and development of CootAdvancing drug innovation for neglected diseases-criteria for lead progressionStructure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effectCreating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug designIs It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target?Small-molecule inhibitors of protein-protein interactions: progressing towards the dreamThe use of proteomics to identify novel therapeutic targets for the treatment of disease.Nanoliter-scale protein crystallization and screening with a microfluidic droplet robot.Understanding the physical properties that control protein crystallization by analysis of large-scale experimental data.Novel Xylene-Linked Maltoside Amphiphiles (XMAs) for Membrane Protein StabilisationFunctional repertoire, molecular pathways and diseases associated with 3D domain swapping in the human proteomeThe XChemExplorer graphical workflow tool for routine or large-scale protein-ligand structure determination.Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium.How much NMR data is required to determine a protein-ligand complex structure?Combinatorial Domain Hunting: An effective approach for the identification of soluble protein domains adaptable to high-throughput applications.Novel inhibitors of anthrax edema factor.Ligand scaffold hopping combining 3D maximal substructure search and molecular similarity.TSCC: Two-Stage Combinatorial Clustering for virtual screening using protein-ligand interactions and physicochemical features.X-ray crystallography of chemical compounds.Rational Tuning of Visual Cycle Modulator PharmacodynamicsRoute to three-dimensional fragments using diversity-oriented synthesis.The benefits of constructing leads from fragment hits.Ace revisited: a new target for structure-based drug design.A conserved glutamate controls the commitment to acyl-adenylate formation in asparagine synthetaseCommercial Licensing of HIV-1 Protease: Applications of the NIH Research Tools Policy.Fragment-based approaches to enzyme inhibition
P2860
Q21142748-420BEF89-4036-430C-AE4F-99F489A4EBACQ24289150-224BFB5C-D591-4CDD-95FF-E73B7484518CQ26853277-FB2B9C4F-F511-41D1-BBF6-18CFA2BB3028Q27316758-5F854929-1DAC-4B33-97D1-1F8102C8AB38Q27316862-7AE2BFBC-B50B-416F-841B-C4F99AF6ECFFQ27655572-84E82741-527F-4236-989B-CEA9D2A6B501Q27667103-248E9F20-3306-4B92-9521-1D4378B36F37Q27670601-E3E56754-9DD2-4C63-915B-6C8A4AC977B3Q27675313-3147BBBC-F15A-479B-8010-92CC680E8F82Q27679154-F8AA9B86-E162-47C4-A786-443B24F58248Q27681364-02C42707-707D-492B-BA18-487E2B40E11DQ27684566-64C0213E-21FB-4B39-B1BF-512DCF0AD846Q27684696-7EB38391-A585-4CF0-B68B-B2A103D630E2Q27700746-E8E8CE17-8214-489E-9E2E-45E8D628924FQ27861079-8A2E6DAE-B2C8-4C9A-8785-BD53892D90AEQ28475996-23AACE72-E7CF-423A-9B32-DD6FDF0D658FQ28477166-F9819CDC-999A-4E99-971C-66B30B72CEF5Q28543133-56D77DE6-6B90-4391-A10F-724C166F9AC1Q28833848-862301B1-F1BF-4485-A684-27CF2A4BD87EQ29617758-A585B829-C130-4268-9D18-E979671CBD53Q30361936-702DBBE5-7C97-4285-9E95-A265EACC7A32Q30367705-05E36460-0EE1-4958-84C6-DAC624D6B08FQ30373905-95773577-67A0-4C03-B4A8-01F11716294CQ30374996-98D6F7D6-C3E8-4A5F-9762-0908857CE516Q30414939-D9047897-7CFD-4ACF-9113-730DE2CFCD41Q30841808-42ACFFEE-AF92-4F80-88BF-C5EEDF192526Q30904604-0901D6E9-237E-4BBD-B133-76663EB4FF2CQ30994008-2DA84BAE-3257-4C60-B549-D278516D5AF0Q33258772-9F653A68-C8BD-470C-BE7C-003F56EC777EQ33351165-3EB3023D-5A11-497E-A6DD-2A6D56551881Q33492553-E122501D-9253-4DA9-8354-E6B20ECC5E25Q33766746-C516F5CD-564A-4CAD-B3B0-95C51A794B88Q33767137-619DF354-8F7D-490B-8AFB-46AD25B4D8BCQ33851022-475558A5-1210-4FF0-A877-AE03824F9B80Q33868796-F77EA190-909F-41D7-92F3-F3BFB6C840B9Q33977454-A8D30064-DAF9-4523-81EE-314AAB6B3482Q34282839-D2740AB2-A949-4622-A7B6-F435530700CFQ34284425-763424EA-B22C-43A2-A23A-2115A5D28CBBQ34452860-2C88DDB7-6247-4931-9F95-35E8D2AC2F47Q34706518-39EFDDF2-386A-412F-8778-DF252ECFF7E4
P2860
High-throughput crystallography for lead discovery in drug design.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
High-throughput crystallography for lead discovery in drug design.
@ast
High-throughput crystallography for lead discovery in drug design.
@en
type
label
High-throughput crystallography for lead discovery in drug design.
@ast
High-throughput crystallography for lead discovery in drug design.
@en
prefLabel
High-throughput crystallography for lead discovery in drug design.
@ast
High-throughput crystallography for lead discovery in drug design.
@en
P356
P1476
High-throughput crystallography for lead discovery in drug design.
@en
P2093
Chris Abell
Harren Jhoti
P2888
P356
10.1038/NRD706
P50
P577
2002-01-01T00:00:00Z